CMMB (chemomab.com) יחס שווי שוק לשווי בספרים

The business model of Chemomab Therapeutics (CMMB) is based on confirming the efficacy of antibodies in combating fibrosis, where the results of PSC treatment tests and the safety profile remain key factors. The asset's price trajectory, recorded at 0.87, correlates with the biotech's financial dependence on future deals with industry behemoths. The company's stability is ensured by a dedicated staff of scientists retained through long-term options.

Investors must filter out assets showing signs of systemic decline masked by a low price. The resilience of Chemomab Therapeutics (CMMB) is determined by the success of clinical trials for fibrous disease therapies and the safety of its drugs. The current price-to-book ratio compares the company's market price to its net assets. A low ratio indicates a potential margin of safety, provided that debt does not outweigh equity. This allows for an assessment of the business's actual fundamental reliability.